Reference is made to the extraordinary general meeting of the Company held on 17 September 2024, where it was resolved to consolidate the Company’s shares. Reference is further made to the warrants issued by the Company pursuant to a resolution by the extraordinary general meeting of the Company held on 16 May 2024 (the “Warrants”). Pursuant to their terms, the Warrants shall be consolidated in the same ratio as the shares. The following key information is provided in connection with the consolidation (reverse split) of the shares and Warrants:
Date on which the corporate action was made public: 17 September 2024.
Consolidation ratio for shares and Warrants: 13 old shares give 1 new share / 13 old Warrants give 1 new Warrant.
Last day including right: 30 September 2024.
Ex-date: 1 October 2024.
Record date: 2 October 2024.
Date of approval: 17 September 2024 (EGM date).
Other information: A new ISIN number will be issued for the shares. Further information will be provided in a separate stock exchange announcement. The Warrants will retain the same ISIN as used today.
This information is published in accordance with the requirements of the Continuing Obligations.
About Lifecare:
Lifecare is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.